49 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
AMC Entertainment (AMC) to Post Q4 Earnings: What's in Store? https://www.zacks.com/stock/news/2232565/amc-entertainment-amc-to-post-q4-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2232565 Feb 27, 2024 - AMC Entertainment's (AMC) fourth-quarter 2023 results are likely to reflect year-over-year growth in attendance on the back of varied service offerings and new theatre openings globally.
Are Investors Undervaluing Carnival (CCL) Right Now? https://www.zacks.com/stock/news/2232408/are-investors-undervaluing-carnival-ccl-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_2-2232408 Feb 27, 2024 - Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Six Flags (SIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release https://www.zacks.com/stock/news/2230241/six-flags-six-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q4-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2230241 Feb 22, 2024 - Six Flags (SIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Offing for Planet Fitness' (PLNT) Q4 Earnings? https://www.zacks.com/stock/news/2229515/what-s-in-the-offing-for-planet-fitness-plnt-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2229515 Feb 21, 2024 - Planet Fitness' (PLNT) fourth-quarter 2023 performance is likely to reflect benefits from the rise in membership sign-ups, strategic partnerships and international expansion.
Marriott Vacations (VAC) to Post Q4 Earnings: What's in Store? https://www.zacks.com/stock/news/2228714/marriott-vacations-vac-to-post-q4-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2228714 Feb 20, 2024 - Marriott Vacations's (VAC) fourth-quarter 2023 performance is likely to have been hurt by lower contract sales.
Live Nation (LYV) Gears Up for Q4 Earnings: What's in Store? https://www.zacks.com/stock/news/2228024/live-nation-lyv-gears-up-for-q4-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2228024 Feb 19, 2024 - Live Nation's (LYV) fourth-quarter 2023 results are likely to reflect the impacts of an increase in demand for live events, a rise in average per-fan spending and a hike in ticket pricing.
Factors Setting the Tone for Choice Hotels' (CHH) Q4 Earnings https://www.zacks.com/stock/news/2228023/factors-setting-the-tone-for-choice-hotels-chh-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2228023 Feb 19, 2024 - Strong booking trends, continuous expansion through acquisitions and franchise agreements are likely to be reflected in Choice Hotels' (CHH) Q4 performance.
What's in Store for PENN Entertainment (PENN) in Q4 Earnings? https://www.zacks.com/stock/news/2225390/what-s-in-store-for-penn-entertainment-penn-in-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2225390 Feb 13, 2024 - PENN Entertainment's (PENN) fourth-quarter 2023 results are likely to reflect benefits from solid growth of gaming revenues.
U.S. IPO Weekly Recap: Autoimmune Biotech Kyverna Therapeutics Gains 37% In A Six IPO Week https://seekingalpha.com/article/4669253-us-ipo-weekly-recap-autoimmune-biotech-kyverna-therapeutics-gains-37-percent-in-a-6-ipo-week?source=feed_tag_ipo_analysis Feb 10, 2024 - Autoimmune disease biotech Kyverna Therapeutics (KYTX) priced above the upwardly revised range to raise $319 million at a $971 million market cap.
MGM Resorts (MGM) to Report Q4 Earnings: What's in the Cards? https://www.zacks.com/stock/news/2224242/mgm-resorts-mgm-to-report-q4-earnings-what-s-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-2224242 Feb 09, 2024 - MGM Resorts' (MGM) fourth-quarter top line is likely to have gained from increased business volume and travel activity at MGM China.

Pages: 12345

<<<Page 3>